Arterys And Therapixel Team Up For AI-powered Breast Cancer Solution
Arterys, a Tempus company, has announced a US and EU distribution agreement with Therapixel, a medical imaging software company providing AI...
During this month's annual Breast Cancer Awareness Month, Arterys highlights current breast cancer statistics, how vital early detection is, and how artificial intelligence imaging is making a solid mark in the ongoing fight.
Current estimates put U.S. breast cancer deaths around 43,780 (43,250 women and 530 men), with female breast cancer being the fifth leading cause of death worldwide. Although research and advancements are making improvements, we currently still face:
The overall death rate from breast cancer decreased by 1% per year from 2013 to 2018. These decreases are partly the result of earlier detection through screening. Other notable facts highlighting the effects of early detection include:
With early detection, diagnosis, and action at the localized stage leading to the highest survival odds, women must be encouraged to seek early screening, such as annual mammograms and digital Tomosynthesis.
Artificial intelligence (AI) is quickly cementing itself as a robust tool for early detection, and Arterys is leading the way as a world-class resource in AI imaging.
Specifically, Arterys' Breast AI solution employs AI to:
Below are four critical ways Arterys' Breast AI solution is helping early breast cancer screenings.
Breast AI is raising the bar on detection performance. It is a high-performing, concurrent-read, cancer-detection and workflow solution that rapidly and accurately analyzes each tomosynthesis image, detecting both malignant soft tissue densities and calcifications with unrivaled accuracy.
Breast AI:
Arterys' cloud-native platform provides enhanced workflows and overall efficiencies.
Breast AI:
With Radiologists facing heavier workflows than ever, making the time between when an imaging exam is acquired and AI results are available to the radiologist (commonly referred to as TAT) has many impacts on workflow and productivity.
Breast AI effectively reduces TAT from 45 minutes to 2 minutes for a cloud solution. A typical breakdown of TAT of a clinical 3D tomosynthesis analyzed with Arterys’ Breast AI can be seen below:
Reducing TAT allows radiologists to speed up workflows and gives patients faster results.
Breast AI offers a clinical decision support tool that provides each woman with an accurate, personalized short-term breast cancer risk estimation.
Breast AI provides clinically proven benefits to clinicians and patients and is designed to optimize efficiency, enhance the patient experience, and improve outcomes. We encourage you to download the data sheet if you want to learn more.
Arterys, a Tempus company, has announced a US and EU distribution agreement with Therapixel, a medical imaging software company providing AI...
The 2023 Society of Breast Imaging (SBI) Breast Imaging Symposium is a must-attend event for radiologists and healthcare professionals involved in...
There are a lot of radiology conferences and events in March, and you can connect with the Arterys team at a number of them! Six specific events in...